Viatris Emerging Markets — Finite-lived intangible assets, net decreased by 10.4% to $2.46B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 10.4%, from $2.74B to $2.46B. This decline may warrant attention — for this metric, higher values are generally preferred.
A high value indicates a strong portfolio of proprietary products or market access rights, while a declining value suggests asset aging or amortization.
The net carrying value of identifiable intangible assets with finite useful lives, such as patents, trademarks, and cust...
Standard metric for pharmaceutical companies reporting 'Intangible Assets' by segment.
vtrs_segment_emerging_markets_finite_lived_intangible_assets_net| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $4.16B | $3.39B | $3.04B | $2.74B | $2.46B |
| QoQ Change | — | -18.6% | -10.4% | -9.6% | -10.4% |
| YoY Change | — | -18.6% | -10.4% | -9.6% | -10.4% |